| |
Partnerships
|
The Company expects to leverage
the value of its technology platform by establishing collaborative arrangements
with leading biotechnology and pharmaceutical companies to identify novel genes
implicated in specific disease states. Strategic alliances that employ
AlphaGene's innovative technologies should complement existing approaches and
accelerate drug discovery via a new high-throughput paradigm for drug
development. |
|
The Company can profit from the formation of these strategic
alliances and subsequently from the development of therapeutic compounds by its
collaborative partners through upfront payments, milestone payments, and
royalties on drug sales.
|
AlphaGene, Inc. has
entered several strategic alliances and scientific collaborations,
including: |
|
Questar,
an international Bioinformatics company, to jointly exploit a selected
number of putative proteins from the AlphaGene novel inventory.
Questar will provide extensive bioinformatic support for structure
determination, pathway identification, and the creation of a library of
potential small molecule ligands for in-silico screening of the small
molecules. In addition, Questar will provide standardization of
database construction and will develop new algorithms for data mining.
|
|
Lahey
Clinic, a group practice of 500 physicians and 4,000 support
staff, to study the molecular genetics of prostate cancer. This
agreement will initially investigate the role of prostate-specific
carcinoembryonic antigen (CEA), recently discovered by AlphaGene's
scientists, as a diagnostic and prognostic marker. Simultaneously,
this collaboration will examine additional genomic and proteomic
methods to understand the molecular biology of prostate cancer, and
possible treatment monitoring protocols.
|
|
Wayne
State University, a leading academic institution located in
Detroit , Michigan, to develop a better understanding of epilepsy. The
agreement will combine the epilepsy expertise of Wayne State
University with the gene expression capabilities of AlphaGene.
The collaboration seeks to identify the genes involved in
the disease pathways, locate logical points of drug intervention, and
develop new therapeutic options in order to provide a better quality
of life for patients with epilepsy.
|
|
DoubleTwist, Inc., a leading e-commerce portal to the genetic
code, to make the AlphaGene gene inventory available to every life
scientist. The collaboration provides researchers with access to
AlphaGene's proprietary cDNA sequence data through DoubleTwist.com. A
DoubleTwist user researching a partial-length DNA sequence will
automatically receive notification when a corresponding full-length
cDNA exists in AlphaGene's database. AlphaGene will give the
DoubleTwist user an opportunity to license or purchase the clone.
|
|
PerkinElmer, previously NEN Life Science
Products ("NEN"), whereby AlphaGene designs, develops, and manufactures a line of gene
expression biochips, which PerkinElmer markets and distributes. The MicroMAX
line of microarrays (MICROMAX™
Human cDNA Microarray System I ) contains known genes from the AlphaGene
gene inventory.
This
agreement has resulted in the development of seven microarrays, one 2,400 gene chip and 6 focused
arrays: Kinase and Phosphatase, Transcription Factors, Human Cancer, Ion
Channels, Apoptosis, and Neuroscience.
|
|
Genetics Institute, now part of Wyeth, a division of American Home
Products, to provide Genetics Institute ("GI") with access to
AlphaGene's full-length, novel human genes encoding for secreted proteins as
part of the DiscoverEase library. AlphaGene was the
largest outside supplier of GI DiscoverEase clones.
|
|
In
addition, AlphaGene has provided various genomic services from library construction
to sequencing for over a dozen customers.
For example, AlphaGene has provided services to the following outstanding
biotechnology companies:
|
|
|
AlphaGene, Inc.
260 W. Cummings Park
Woburn, MA 01801
|
info@alphagene.com
781.933.4446 phone
781.933.5424 fax
|
|